

List of Publications

Currently 162 Peer reviewed research articles; H-index 26, total Cites: 2269

Scopus EXPORT DATE: 8.5.2018

1. C Vraka, L Nics, KH Wagner, M Hacker, W Wadsak, M Mitterhauser. **LogP, a yesterday's value?** *Nuclear Medicine and Biology*. 2017;50:1-10.
2. Mitterhauser M, Wadsak W. **Imaging biomarkers or biomarker imaging?** *Pharmaceuticals*, 2014,7:765-778.
3. Mitterhauser M, Toegel S. **Radiopharmaceutical considerations on bone seeker uptake: Should we learn from therapeutical targets of bisphosphonates?** *Nuclear Medicine and Biology*, 2011 38:617-8.
4. Wadsak W, Mitterhauser M. **Basics and principles of radiopharmaceuticals for PET/CT** *European Journal of Radiology*, 2010,73:461-9.
5. Mitterhauser M and Toegel S. **An *in-vitro* Model for the Comparative Evaluation of Bone seeking Pharmaceuticals.** *Altex* 2008;25:51-5.

First authorship

1. **Imaging biomarkers or biomarker imaging?** M Mitterhauser, W Wadsak. *Pharmaceuticals*. 2014;7(7):765-78.
2. **Radiopharmaceutical considerations on bone seeker uptake: Should we learn from therapeutical targets of bisphosphonates?** M Mitterhauser, S Toegel. *Nuclear Medicine and Biology*. 2011;38(5):617-8.
3. **An in vitro model for the comparative evaluation of bone seeking pharmaceuticals.** M Mitterhauser, S Toegel. *Altex*. 2008;25(1):51-5.
4. **What to consider in the development of new bone seekers: mechanistic and tracer-related aspects.** M Mitterhauser, S Toegel. *Nuclear Medicine and Biology*. 2008;35(8):817-24.
5. **Evaluation of novel tropane analogues.** M Mitterhauser, W Wadsak. *Nuclear Medicine and Biology*. 2007;34(5):591-2.
6. **Pre vivo, ex vivo and in vivo evaluations of [68Ga]-EDTMP.** M Mitterhauser, S Toegel, W Wadsak, RR Lanzenberger, LK Mien, C Kuntner, T Wanek, H Eidherr, DE Ettliger, H Viernstein, R Kluger, R Dudczak, K Kletter. *Nuclear Medicine and Biology*. 2007;34(4):391-7.
7. **Imaging of adrenocortical metastases with [11C]metomidate.** M Mitterhauser, G Dobrozemsky, G Zettinig, W Wadsak, H Vierhapper, R Dudczak, K Kletter. *European Journal of Nuclear Medicine and Molecular Imaging*. 2006;33(8):974.
8. **Binding studies of [18F]-fluoride and polyphosphonates radiolabelled with [99mTc], [111In], [153Sm] and [188Re] on bone compartments: Verification of the pre vivo model?** M Mitterhauser, S Toegel, W Wadsak, LK Mien, H Eidherr, K Kletter, H Viernstein, R Kluger, A Engel, R Dudczak. *Bone*. 2005;37(3):404-12.
9. **New aspects on the preparation of [11C]Methionine - A simple and fast online approach without preparative HPLC.** M Mitterhauser, W Wadsak, A Krcal, J Schmaljohann, H Eidherr, A Schmid, H Viernstein, R Dudczak, K Kletter. *Applied Radiation and Isotopes*. 2005;62(3):441-5.
10. **Synthesis and biodistribution of [18F]FE@CIT, a new potential tracer for the dopamine transporter.** M Mitterhauser, W Wadsak, LK Mien, A Hoepfing, H Viernstein, R Dudczak, K Kletter. *Synapse*. 2005;55(2):73-9.
11. **New aspects on the preparation of [11C]acetate - A simple and fast approach via distillation.** M Mitterhauser, W Wadsak, A Krcal, J Schmaljohann, E Bartosch, H Eidherr, H Viernstein, K Kletter. *Applied Radiation and Isotopes*. 2004;61(6):1147-50.
12. **Binding studies of [18F]-fluoride and polyphosphonates radiolabelled with [111In], [99mTc], [153Sm], and [188Re] on bone compartments: A new model**

- for the pre vivo evaluation of bone seekers?** M Mitterhauser, S Tögel, W Wadsak, LK Mien, H Eidherr, K Wiesner, H Viernstein, K Kletter, R Dudczak. *Bone*. 2004;34(5):835-44.
13. **Labelling of EDTMP (Multibone®) with [111In], [99mTc] and [188Re] using different carriers for "cross complexation".** M Mitterhauser, W Wadsak, H Eidherr, A Krcal, K Kletter, R Dudczak, H Viernstein, C Pirich. *Applied Radiation and Isotopes*. 2004;60(5):653-8.
 14. **Biological evaluation of 2'-[18F]fluoroflumazenil ([18F]FFMZ), a potential GABA receptor ligand for PET.** M Mitterhauser, W Wadsak, L Wabnegger, LK Mien, S Tögel, O Langer, W Sieghart, H Viernstein, K Kletter, R Dudczak. *Nuclear Medicine and Biology*. 2004;31(2):291-5.
 15. **In vivo and in vitro evaluation of [18F]FETO with respect to the adrenocortical and GABAergic system in rats.** M Mitterhauser, W Wadsak, L Wabnegger, W Sieghart, H Viernstein, K Kletter, R Dudczak. *European Journal of Nuclear Medicine and Molecular Imaging*. 2003;30(10):1398-401.
 16. **Comparison of three different purification methods for the routine preparation of [11C] metomidate.** M Mitterhauser, W Wadsak, O Langer, J Schmaljohann, G Zetting, R Dudczak, H Viernstein, K Kletter. *Applied Radiation and Isotopes*. 2003;59(2-3):125-8.
 17. **The labelling of Nanocoll® with [111In] for dual-isotope scanning.** M Mitterhauser, W Wadsak, LK Mien, H Eidherr, S Roka, G Zetting, P Angelberger, H Viernstein, K Kletter, R Dudczak. *Applied Radiation and Isotopes*. 2003;59(5-6):337-42.

Senior authorships

18. **A new method measuring the interaction of radiotracers with the human P-glycoprotein (P-gp) transporter.** C Vranka, M Dumanic, T Racz, F Pichler, C Philippe, T Balber, EM Klebermass, KH Wagner, M Hacker, W Wadsak, M Mitterhauser. *Nuclear Medicine and Biology*. 2018;60:29-36.
19. **Expanding LogP: Present possibilities.** C Vranka, S Mijailovic, V Fröhlich, M Zeilinger, EM Klebermass, W Wadsak, KH Wagner, M Hacker, M Mitterhauser. *Nuclear Medicine and Biology*. 2018;58:20-32.
20. **LogP, a yesterday's value?** C Vranka, L Nics, KH Wagner, M Hacker, W Wadsak, M Mitterhauser. *Nuclear Medicine and Biology*. 2017;50:1-10.
21. **New approaches for the reliable in vitro assessment of binding affinity based on high-resolution real-time data acquisition of radioligand-receptor binding kinetics.** M Zeilinger, F Pichler, L Nics, W Wadsak, H Spreitzer, M Hacker, M Mitterhauser. *EJNMMI Research*. 2017;7(1).
22. **[18F]FE@SNAP—a specific PET tracer for melanin-concentrating hormone receptor 1 imaging?** C Philippe, D Haeusler, T Scherer, C Fürnsinn, M Zeilinger, W Wadsak, K Shanab, H Spreitzer, M Hacker, M Mitterhauser. *EJNMMI Research*. 2016;6(1).
23. **[18F]FMENER-D2: A systematic in vitro analysis of radio-metabolism.** C Rami-Mark, N Eberherr, N Berroterán-Infante, T Vanicek, L Nics, R Lanzenberger, M Hacker, W Wadsak, M Mitterhauser. *Nuclear Medicine and Biology*. 2016;43(8):490-5.
24. **Hide and seek: a comparative autoradiographic in vitro investigation of the adenosine A3 receptor.** D Haeusler, L Grassinger, F Fuchshuber, WJ Hörleinsberger, R Höftberger, I Leisser, F Girschele, K Shanab, H Spreitzer, W Gerdenitsch, M Hacker, W Wadsak, M Mitterhauser. *European Journal of Nuclear Medicine and Molecular Imaging*. 2015;42(6):928-39.
25. **[18F]FE@SUPPY: a suitable PET tracer for the adenosine A3 receptor? An in vivo study in rodents.** D Haeusler, C Kuntner, L Nics, M Savli, M Zeilinger, T Wanek, P Karagiannis, RR Lanzenberger, O Langer, K Shanab, H Spreitzer, W Wadsak, M Hacker, M Mitterhauser. *European Journal of Nuclear Medicine and Molecular Imaging*. 2015;42(5):741-9.

26. **Comparative autoradiographic in vitro investigation of melanin concentrating hormone receptor 1 ligands in the central nervous system.** C Philippe, D Haeusler, F Fuchshuber, H Spreitzer, H Viernstein, M Hacker, W Wadsak, M Mitterhauser. *European Journal of Pharmacology*. 2014;735(1):177-83.
27. **Preclinical in vitro & in vivo evaluation of [11C]SNAP-7941 - the first PET tracer for the melanin concentrating hormone receptor 1.** C Philippe, L Nics, M Zeilinger, C Kuntner, T Wanek, S Mairinger, K Shanab, H Spreitzer, H Viernstein, W Wadsak, M Mitterhauser. *Nuclear Medicine and Biology*. 2013;40(7):919-25.
28. **Preparation and first preclinical evaluation of [18F]FE@SNAP: A potential PET tracer for the melanin-concentrating hormone receptor-1 (MCHR1).** C Philippe, L Nics, M Zeilinger, E Schirmer, H Spreitzer, G Karanikas, R Lanzenberger, H Viernstein, W Wadsak, M Mitterhauser. *Scientia Pharmaceutica*. 2013;81(3):625-39.
29. **Quantification of the radio-metabolites of the serotonin-1A receptor radioligand [carbonyl-11C]WAY-100635 in human plasma: An HPLC-assay which enables measurement of two patients in parallel.** L Nics, A Hahn, M Zeilinger, C Vraka, J Ungersboeck, D Haeusler, S Hartmann, KH Wagner, R Lanzenberger, W Wadsak, M Mitterhauser. *Applied Radiation and Isotopes*. 2012;70(12):2730-6.
30. **[18F]FE@SUPPY and [18F]FE@SUPPY:2 - metabolic considerations.** D Haeusler, L Nics, LK Mien, J Ungersboeck, RR Lanzenberger, K Shanab, H Spreitzer, KM Sindelar, H Viernstein, KH Wagner, R Dudczak, K Kletter, W Wadsak, M Mitterhauser. *Nuclear Medicine and Biology*. 2011;38(3):449.
31. **The stability of methyl-, ethyl- and fluoroethylesters against carboxylesterases in vitro: There is no difference.** L Nics, D Haeusler, W Wadsak, KH Wagner, R Dudczak, K Kletter, M Mitterhauser. *Nuclear Medicine and Biology*. 2011;38(1):13-7.
32. **[18F]FE@SUPPY and [18F]FE@SUPPY:2 - metabolic considerations.** D Haeusler, L Nics, LK Mien, J Ungersboeck, RR Lanzenberger, K Shanab, KM Sindelar, H Viernstein, KH Wagner, R Dudczak, K Kletter, W Wadsak, M Mitterhauser. *Nuclear Medicine and Biology*. 2010;37(4):421-6.
33. **"Label and go" - A fast and easy radiolabelling method for pellets.** C Philippe, LK Mien, S Salar-Behzadi, B Knäusl, W Wadsak, R Dudczak, K Kletter, H Viernstein, M Mitterhauser. *Applied Radiation and Isotopes*. 2010;68(3):399-403.
34. **Basics and principles of radiopharmaceuticals for PET/CT.** W Wadsak, M Mitterhauser. *European Journal of Radiology*. 2010;73(3):461-9.
35. **Metabolism and autoradiographic evaluation of [18F]FE@CIT: a Comparison with [123I]β-CIT and [123I]FP-CIT.** DE Ettliger, D Häusler, W Wadsak, F Girschele, KM Sindelar, LK Mien, J Ungersböck, H Viernstein, K Kletter, R Dudczak, M Mitterhauser. *Nuclear Medicine and Biology*. 2008;35(4):475-9.
36. **Preparation and pre-vivo evaluation of no-carrier-added, carrier-added and cross-complexed [68Ga]-EDTMP formulations.** S Toegel, W Wadsak, LK Mien, H Viernstein, R Kluger, H Eidherr, D Haeusler, K Kletter, R Dudczak, M Mitterhauser. *European Journal of Pharmaceutics and Biopharmaceutics*. 2008;68(2):406-12.
37. **Radiosynthesis of the adenosine A3 receptor ligand 5-(2-[18F]fluoroethyl) 2,4-diethyl-3-(ethylsulfonylcarbonyl)-6- phenylpyridine-5-carboxylate ([18F]FE@SUPPY).** W Wadsak, LK Mien, K Shanab, K Weber, B Schmidt, KM Sindelar, DE Ettliger, D Haeusler, H Spreitzer, BK Keppler, H Viernstein, R Dudczak, K Kletter, M Mitterhauser. *Radiochimica Acta*. 2008;96(2):119-24.
38. **Preparation and first evaluation of [18F]FE@SUPPY: a new PET tracer for the adenosine A3 receptor.** W Wadsak, LK Mien, K Shanab, DE Ettliger, D Haeusler, K Sindelar, RR Lanzenberger, H Spreitzer, H Viernstein, BK Keppler, R Dudczak, K Kletter, M Mitterhauser. *Nuclear Medicine and Biology*. 2008;35(1):61-6.
39. **18F fluoroethylations: different strategies for the rapid translation of 11C-methylated radiotracers.** W Wadsak, LK Mien, DE Ettliger, H Eidherr, D Haeusler, KM Sindelar, BK Keppler, R Dudczak, K Kletter, M Mitterhauser. *Nuclear Medicine and Biology*. 2007;34(8):1019-28.
40. **Simple and fully automated preparation of [carbonyl-11C]WAY- 100635.** W Wadsak, LK Mien, DE Ettliger, RR Lanzenberger, D Haeusler, R Dudczak, K Kletter, M Mitterhauser. *Radiochimica Acta*. 2007;95(7):417-22.

41. **Preparation and radiosynthesis of [18F]FE@CFN (2-[18F]fluoroethyl 4-[N-(1-oxopropyl)-N-phenylamino]-1-(2-phenylethyl)-4-piperidinecarboxylate): A potential μ -opioid receptor imaging agent.** W Wadsak, L Key Mien, DE Ettliger, S Feitscher, R Lanzenberger, J Marton, R Dudczak, K Kletter, M Mitterhauser. *Radiochimica Acta*. 2007;95(1):33-8.
42. **[18F]FETO: Metabolic considerations.** DE Ettliger, W Wadsak, LK Mien, M Machek, L Wabnegger, G Rendl, G Karanikas, H Viernstein, K Kletter, R Dudczak, M Mitterhauser. *European Journal of Nuclear Medicine and Molecular Imaging*. 2006;33(8):928-31.
43. **Uptake of bone-seekers is solely associated with mineralisation! A study with 99mTc-MDP, 153Sm-EDTMP and 18F-fluoride on osteoblasts.** S Toegel, O Hoffmann, W Wadsak, D Ettliger, LK Mien, K Wiesner, J Nguemo, H Viernstein, K Kletter, R Dudczak, M Mitterhauser. *European Journal of Nuclear Medicine and Molecular Imaging*. 2006;33(4):491-4.
44. **In vitro evaluation of no carrier added, carrier added and cross-complexed [90Y]-EDTMP provides evidence for a novel "foreign carrier theory".** S Toegel, LK Mien, W Wadsak, H Eindherr, H Viernstein, R Kluger, D Ettliger, K Kletter, R Dudczak, M Mitterhauser. *Nuclear Medicine and Biology*. 2006;33(1):95-9.
45. **Synthesis of [18F]FETO, a novel potential 11- β hydroxylase inhibitor.** W Wadsak, M Mitterhauser. *Journal of Labelled Compounds and Radiopharmaceuticals*. 2003;46(4):379-88.

Co-authorships:

46. **FEPPA: Improved Automated Radiosynthesis, Binding Affinity, and Preliminary in Vitro Evaluation in Colorectal Cancer.** N Berroterán-Infante, T Balber, P Furlinger, M Bergmann, R Lanzenberger, M Hacker, M Mitterhauser, W Wadsak. *ACS Medicinal Chemistry Letters*. 2018;9(3):177-81.
47. **Changes in Tumor Biology During Chemoradiation of Cervix Cancer Assessed by Multiparametric MRI and Hypoxia PET.** P Georg, P Andrzejewski, P Baltzer, M Daniel, W Wadsak, M Mitterhauser, A Sturdza, K Majercakova, G Karanikas, R Pötter, M Hacker, T Helbich, D Georg, K Pinker. *Molecular Imaging and Biology*. 2018;20(1):160-9.
48. **Task-relevant brain networks identified with simultaneous PET/MR imaging of metabolism and connectivity.** A Hahn, G Gryglewski, L Nics, L Rischka, S Ganger, H Sigurdardottir, C Vraka, L Silberbauer, T Vanicek, A Kautzky, W Wadsak, M Mitterhauser, M Hartenbach, M Hacker, S Kasper, R Lanzenberger. *Brain Structure and Function*. 2018;223(3):1369-78.
49. **Probing the association between serotonin-1A autoreceptor binding and amygdala reactivity in healthy volunteers.** GS Kranz, A Hahn, C Kraus, M Spies, V Pichler, J Jungwirth, M Mitterhauser, W Wadsak, C Windischberger, S Kasper, R Lanzenberger. *NeuroImage*. 2018;171:1-5.
50. **[68Ga]Pentixafor-PET/MRI for the detection of Chemokine receptor 4 expression in atherosclerotic plaques.** X Li, D Heber, T Leike, D Beitzke, X Lu, X Zhang, Y Wei, M Mitterhauser, W Wadsak, S Kropf, HJ Wester, C Loewe, M Hacker, AR Haug. *European Journal of Nuclear Medicine and Molecular Imaging*. 2018;45(4):558-66.
51. **Speed matters to raise molar radioactivity: Fast HPLC shortens the quality control of C-11 PET-tracers.** L Nics, B Steiner, EM Klebermass, C Philippe, M Mitterhauser, M Hacker, W Wadsak. *Nuclear Medicine and Biology*. 2018;57:28-33.
52. **EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.** TD Poeppel, D Handkiewicz-Junak, M Andreeff, A Becherer, A Bockisch, E Fricke, L Geworski, A Heinzl, BJ Krause, T Krause, M Mitterhauser, W Sonnenschein, L Bodei, RC Delgado-Bolton, M Gabriel. *European Journal of Nuclear Medicine and Molecular Imaging*. 2018;45(5):824-45.
53. **Visual and semiquantitative 11C-methionine PET: An independent prognostic factor for survival of newly diagnosed and treatment-naïve gliomas.** N Poetsch, A Woehrer, J Gesperger, J Furtner, AR Haug, D Wilhelm, G Widhalm, G Karanikas, M

- Weber, I Rausch, M Mitterhauser, W Wadsak, M Hacker, M Preusser, T Traub-Weidinger. *Neuro-Oncology*. 2018;20(3):411-9.
54. **Assessment of Ketamine binding of the serotonin transporter in humans with positron emission tomography.** M Spies, GM James, N Berroterán-Infante, H Ibeschitz, GS Kranz, J Unterholzner, M Godbersen, G Gryglewski, M Hienert, J Jungwirth, V Pichler, B Reiter, L Silberbauer, D Winkler, M Mitterhauser, T Stimpfl, M Hacker, S Kasper, R Lanzenberger. *International Journal of Neuropsychopharmacology*. 2018;21(2):145-53.
 55. **In vivo magnetic resonance imaging of pancreatic tumors using iron oxide nanoworms targeted with PTR86 peptide.** Y Ahmadi, G Kostenich, M Oron-Herman, W Wadsak, M Mitterhauser, A Orenstein, S Mirzaei, P Knoll. *Colloids and Surfaces B: Biointerfaces*. 2017;158:423-30.
 56. **Impact of hybrid PET/MR technology on multiparametric imaging and treatment response assessment of cervix cancer.** M Daniel, P Andrzejewski, A Sturdza, K Majercakova, P Baltzer, K Pinker, W Wadsak, M Mitterhauser, R Pötter, P Georg, T Helbich, D Georg. *Radiotherapy and Oncology*. 2017;125(3):420-5.
 57. **Development of a radiolabeled caninized anti-EGFR antibody for comparative oncology trials.** J Fazekas-Singer, N Berroterán-Infante, C Rami-Mark, M Dumanic, M Matz, M Willmann, F Andreae, J Singer, W Wadsak, M Mitterhauser, E Jensen-Jarolim. *Oncotarget*. 2017;8(47):83128-41.
 58. **Simple and rapid quantification of serotonin transporter binding using [11C]DASB bolus plus constant infusion.** G Gryglewski, L Rischka, C Philippe, A Hahn, GM James, E Klebermass, M Hienert, L Silberbauer, T Vanicek, A Kautzky, N Berroterán-Infante, L Nics, T Traub-Weidinger, M Mitterhauser, W Wadsak, M Hacker, S Kasper, R Lanzenberger. *NeuroImage*. 2017;149:23-32.
 59. **Effects of selective serotonin reuptake inhibitors on interregional relation of serotonin transporter availability in major depression.** GM James, P Baldinger-Melich, C Philippe, GS Kranz, T Vanicek, A Hahn, G Gryglewski, M Hienert, M Spies, T Traub-Weidinger, M Mitterhauser, W Wadsak, M Hacker, S Kasper, R Lanzenberger. *Frontiers in Human Neuroscience*. 2017;11.
 60. **The influence of the rs6295 gene polymorphism on serotonin-1A receptor distribution investigated with PET in patients with major depression applying machine learning.** A Kautzky, GM James, C Philippe, P Baldinger-Melich, C Kraus, GS Kranz, T Vanicek, G Gryglewski, W Wadsak, M Mitterhauser, D Rujescu, S Kasper, R Lanzenberger. *Translational psychiatry*. 2017;7(6):e1150.
 61. **Association of Protein Distribution and Gene Expression Revealed by PET and Post-Mortem Quantification in the Serotonergic System of the Human Brain.** A Komorowski, GM James, C Philippe, G Gryglewski, A Bauer, M Hienert, M Spies, A Kautzky, T Vanicek, A Hahn, T Traub-Weidinger, D Winkler, W Wadsak, M Mitterhauser, M Hacker, S Kasper, R Lanzenberger. *Cerebral cortex (New York, NY : 1991)*. 2017;27(1):117-30.
 62. **The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab.** S Li, M Peck-Radosavljevic, P Ubl, W Wadsak, M Mitterhauser, E Rainer, M Pinter, H Wang, C Nanoff, K Kaczirek, A Haug, M Hacker. *European Journal of Nuclear Medicine and Molecular Imaging*. 2017;44(10):1732-41.
 63. **Association between osteogenesis and inflammation during the progression of calcified plaque evaluated by 18F-Fluoride and 18F-FDG.** X Li, D Heber, JC Gonzalez, G Karanikas, ME Mayerhoefer, S Rasul, D Beitzke, X Zhang, H Agis, M Mitterhauser, W Wadsak, T Beyer, C Loewe, M Hacker. *Journal of Nuclear Medicine*. 2017;58(6):968-74.
 64. **Multiparametric [11C]Acetate positron emission tomography-magnetic resonance imaging in the assessment and staging of prostate cancer.** SH Polanec, P Andrzejewski, PAT Baltzer, TH Helbich, A Stiglbauer, D Georg, G Karanikas, M Susani, W Wadsak, M Margreiter, M Mitterhauser, P Brader, K Pinker. *PLoS ONE*. 2017;12(7).

65. **** -Postprandial pancreatic [11C]methionine uptake after pancreaticoduodenectomy mirrors basal beta cell function and insulin release.** E Steiner, L Kazianka, R Breuer, M Hacker, W Wadsak, M Mitterhauser, T Stimpfl, B Reiter, G Karanikas, J Miholic. *European Journal of Nuclear Medicine and Molecular Imaging*. 2017;44(3):509-16.
66. **Altered interregional molecular associations of the serotonin transporter in attention deficit/hyperactivity disorder assessed with PET.** T Vanicek, A Kutzelnigg, C Philippe, HL Sigurdardottir, GM James, A Hahn, GS Kranz, A Höflich, A Kautzky, T Traub-Weidinger, M Hacker, W Wadsak, M Mitterhauser, S Kasper, R Lanzenberger. *Human Brain Mapping*. 2017;38(2):792-802.
67. **Reconsider logP!** C Vraka, M Mitterhauser. *Nuclear Medicine and Biology*. 2017;54:42.
68. **In vivo evaluation of radiotracers targeting the melanin-concentrating hormone receptor 1: [11C]SNAP-7941 and [18F]FE@SNAP reveal specific uptake in the ventricular system.** M Zeilinger, M Dumanic, F Pichler, L Budinsky, W Wadsak, K Pallitsch, H Spreitzer, R Lanzenberger, M Hacker, M Mitterhauser, C Philippe. *Scientific Reports*. 2017;7(1).
69. **Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/contrast-enhanced computed tomography (18F-DOPA PET/CT) in patients with suspected paraganglioma.** K El-Rabadi, M Weber, M Mayerhofer, T Nakuz, T Scherer, M Mitterhauser, R Dudczak, M Hacker, G Karanikas. *Anticancer Research*. 2016;36(8):4187-93.
70. **Quantification of task-specific glucose metabolism with constant infusion of 18F-FDG.** A Hahn, G Gryglewski, L Nics, M Hienert, L Rischka, C Vraka, H Sigurdardottir, T Vanicek, GM James, R Seiger, A Kautzky, L Silberbauer, W Wadsak, M Mitterhauser, M Hacker, S Kasper, R Lanzenberger. *Journal of Nuclear Medicine*. 2016;57(12):1933-40.
71. **Erratum to: Quantitative assessment of atherosclerotic plaques on 18F-FDG PET/MRI: comparison with a PET/CT hybrid system (Eur J Nucl Med Mol Imaging, DOI 10.1007/s00259-016-3308-6).** X Li, D Heber, I Rausch, D Beitzke, ME Mayerhoefer, S Rasul, M Kreissl, M Mitterhauser, W Wadsak, M Hartenbach, A Haug, X Zhang, C Loewe, T Beyer, M Hacker. *European Journal of Nuclear Medicine and Molecular Imaging*. 2016;43(8):1569.
72. **Multiparametric [18F]fluorodeoxyglucose/[18F]fluoromisonidazole positron emission tomography/ magnetic resonance imaging of locally advanced cervical cancer for the non-invasive detection of tumor heterogeneity: A pilot study.** K Pinker, P Andrzejewski, P Baltzer, SH Polanec, A Sturdza, D Georg, TH Helbich, G Karanikas, C Grimm, S Polterauer, R Poetter, W Wadsak, M Mitterhauser, P Georg. *PLoS ONE*. 2016;11(5).
73. **Therapy of bone metastases with radium-223 German guidelines.** TD Pöppel, M Andreeff, A Becherer, A Bockisch, E Fricke, L Geworski, A Heinzl, BJ Krause, T Krause, M Mitterhauser, K Scheidhauer, M Schenck, W Sonnenschein, M Gabriel. *NuklearMedizin*. 2016;55(5):177-86.
74. **Effects of norepinephrine transporter gene variants on NET binding in ADHD and healthy controls investigated by PET.** HL Sigurdardottir, GS Kranz, C Rami-Mark, GM James, T Vanicek, G Gryglewski, A Kautzky, M Hienert, T Traub-Weidinger, M Mitterhauser, W Wadsak, M Hacker, D Rujescu, S Kasper, R Lanzenberger. *Human Brain Mapping*. 2016;37(3):884-95.
75. **Development of a Novel Nonpeptidic 18F-Labeled Radiotracer for in Vivo Imaging of Oxytocin Receptors with Positron Emission Tomography.** B Wenzel, J Mollitor, W Deuther-Conrad, S Dukic-Stefanovic, M Kranz, C Vraka, R Teodoro, R Günther, CK Donat, FA Ludwig, S Fischer, R Smits, W Wadsak, M Mitterhauser, J Steinbach, A Hoepfing, P Brust. *Journal of Medicinal Chemistry*. 2016;59(5):1800-17.
76. **Interaction between 5-HTTLPR and 5-HT1B genotype status enhances cerebral 5-HT1A receptor binding.** P Baldinger, C Kraus, C Rami-Mark, G Gryglewski, GS Kranz, D Haeusler, A Hahn, M Spies, W Wadsak, M Mitterhauser, D Rujescu, S Kasper, R Lanzenberger. *NeuroImage*. 2015;111:505-12.

77. **High-dose testosterone treatment increases serotonin transporter binding in transgender people.** GS Kranz, W Wadsak, U Kaufmann, M Savli, P Baldinger, G Gryglewski, D Haeusler, M Spies, M Mitterhauser, S Kasper, R Lanzenberger. *Biological Psychiatry*. 2015;78(8):525-33.
78. **Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [11C]acetate PET as a prognostic marker.** A Leisser, K Pruscha, P Ubl, W Wadsak, M Mayerhöfer, M Mitterhauser, M Hacker, G Kramer, S Shariat, G Karanikas, M Hartenbach, AR Haug. *Prostate*. 2015;75(15):1760-7.
79. **1-(3-Amino-1-phenylpropyl)-3-(2-fluorophenyl)-1,3-dihydro-2H-benzimidazol-2-one.** C Neudorfer, N Eberherr, K Shanab, W Holzer, C Rami-Mark, M Mitterhauser, W Wadsak, H Spreitzer. *MolBank*. 2015;2015(3).
80. **2-fluoro-N-methyl-N-[(3s*,4s*)-4-(2-methylphenoxy)-3,4-dihydro-1H-isochromen-3-yl]methyl}ethanamine.** C Neudorfer, K Shanab, W Holzer, C Rami-Mark, M Mitterhauser, W Wadsak, H Spreitzer. *MolBank*. 2015;2015(2).
81. **2-Fluoro-N-methyl-N-[(3S,4S)-4-[2-(trifluoromethyl)phenoxy]-3,4-dihydro-1H-isochromen-3-yl]methyl}ethanamine.** C Neudorfer, K Shanab, W Holzer, C Rami-Mark, M Mitterhauser, W Wadsak, H Spreitzer. *MolBank*. 2015;2015(2).
82. **Synthesis and in silico evaluation of novel compounds for PET-based investigations of the norepinephrine transporter.** C Neudorfer, A Seddik, K Shanab, A Jurik, C Rami-Mark, W Holzer, G Ecker, M Mitterhauser, W Wadsak, H Spreitzer. *Molecules*. 2015;20(1):1712-30.
83. **Parameter evaluation and fully-automated radiosynthesis of [11C]harmine for imaging of MAO-A for clinical trials.** C Philippe, M Zeilinger, M Mitterhauser, M Dumanic, R Lanzenberger, M Hacker, W Wadsak. *Applied Radiation and Isotopes*. 2015;97:182-7.
84. **Radiosynthesis and first preclinical evaluation of the novel norepinephrine transporter pet-ligand [11C]ME@HAPTHI.** C Rami-Mark, N Berroterán-Infante, C Philippe, S Foltin, C Vranka, A Hoepfing, R Lanzenberger, M Hacker, M Mitterhauser, W Wadsak. *EJNMMI Research*. 2015;5(1).
85. **Detection of Bone Metastases Using 11C-Acetate PET in Patients with Prostate Cancer with Biochemical Recurrence.** C Spick, SH Polanec, M Mitterhauser, W Wadsak, P Anner, B Reiterits, AR Haug, M Hacker, M Beheshti, G Karanikas. *Anticancer research*. 2015;35(12):6787-91.
86. **Regional differences in SERT occupancy after acute and prolonged SSRI intake investigated by brain PET.** P Baldinger, GS Kranz, D Haeusler, M Savli, M Spies, C Philippe, A Hahn, A Höflich, W Wadsak, M Mitterhauser, R Lanzenberger, S Kasper. *NeuroImage*. 2014;88:252-62.
87. **Effects of silexan on the serotonin-1A receptor and microstructure of the human brain: A randomized, placebo-controlled, double-blind, cross-over study with molecular and structural neuroimaging.** P Baldinger, AS Höflich, M Mitterhauser, A Hahn, C Rami-Mark, M Spies, W Wadsak, R Lanzenberger, S Kasper. *International Journal of Neuropsychopharmacology*. 2014;18(4):1-9.
88. **Impact of COMT genotype on serotonin-1A receptor binding investigated with PET.** P Baldinger, A Hahn, M Mitterhauser, GS Kranz, M Friedl, W Wadsak, C Kraus, J Ungersböck, A Hartmann, I Giegling, D Rujescu, S Kasper, R Lanzenberger. *Brain Structure and Function*. 2014;219(6):2017-28.
89. **In vivo P-glycoprotein function before and after epilepsy surgery.** M Bauer, R Karch, M Zeitlinger, J Liu, MJ Koepp, MC Asselin, SM Sisodiya, JA Hainfellner, W Wadsak, M Mitterhauser, M Müller, E Pataraiia, O Langer. *Neurology*. 2014;83(15):1326-31.
90. **Attenuated serotonin transporter association between dorsal raphe and ventral striatum in major depression.** A Hahn, D Haeusler, C Kraus, AS Höflich, GS Kranz, P Baldinger, M Savli, M Mitterhauser, W Wadsak, G Karanikas, S Kasper, R Lanzenberger. *Human Brain Mapping*. 2014;35(8):3857-66.
91. **Effects of hormone replacement therapy on cerebral serotonin-1A receptor binding in postmenopausal women examined with [carbonyl-11C]WAY-100635.** GS Kranz, C Rami-Mark, U Kaufmann, P Baldinger, A Hahn, A Höflich, M Savli, P Stein, W

- Wadsak, M Mitterhauser, D Winkler, R Lanzenberger, S Kasper. *Psychoneuroendocrinology*. 2014;45:1-10.
92. **Cerebral serotonin transporter asymmetry in females, males and male-to-female transsexuals measured by PET in vivo.** GS Kranz, A Hahn, P Baldinger, D Haeusler, C Philippe, U Kaufmann, W Wadsak, M Savli, A Hoeflich, C Kraus, T Vanicek, M Mitterhauser, S Kasper, R Lanzenberger. *Brain Structure and Function*. 2014;219(1):171-83.
 93. **Exploring the impact of BDNF Val66Met genotype on serotonin transporter and serotonin-1A receptor binding.** C Kraus, P Baldinger, C Rami-Mark, G Gryglewsky, GS Kranz, D Haeusler, A Hahn, W Wadsak, M Mitterhauser, D Rujescu, S Kasper, R Lanzenberger. *PLoS ONE*. 2014;9(9).
 94. **18F-DOPA PET/CT and MRI: Description of 12 histologically-verified pheochromocytomas.** S Magnaldi, ME Mayerhoefer, A Khameneh, M Schuetz, D Javor, M Mitterhauser, R Dudczak, M Hacker, G Karanikas. *Anticancer Research*. 2014;34(2):791-6.
 95. **Development of potential selective and reversible pyrazoline based MAO-B inhibitors as MAO-B PET tracer precursors and reference substances for the early detection of Alzheimer's disease.** C Neudorfer, K Shanab, A Jurik, V Schreiber, C Neudorfer, C Vranka, E Schirmer, W Holzer, G Ecker, M Mitterhauser, W Wadsak, H Spreitzer. *Bioorganic and Medicinal Chemistry Letters*. 2014;24(18):4490-5.
 96. **Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats.** P Schwabl, BA Payer, J Grahovac, S Klein, T Horvatits, M Mitterhauser, J Stift, Y Boucher, J Trebicka, M Trauner, B Angermayr, V Fuhrmann, T Reiberger, M Peck-Radosavljevic. *Journal of Hepatology*. 2014;60(6):1135-42.
 97. **A One-Step microwave-assisted synthetic method for an o/s-chemoselective route to derivatives of the first adenosine a3 pet radiotracer.** K Shanab, C Neudorfer, W Holzer, M Mitterhauser, W Wadsak, H Spreitzer. *Molecules*. 2014;19(4):4076-82.
 98. **Relation of progesterone and DHEAS serum levels to 5-HT1A receptor binding potential in pre- and postmenopausal women.** P Stein, P Baldinger, U Kaufmann, RM Christina, A Hahn, A Höflich, GS Kranz, M Savli, W Wadsak, M Mitterhauser, D Winkler, S Kasper, R Lanzenberger. *Psychoneuroendocrinology*. 2014;46:52-63.
 99. **11C-Methionine PET/CT imaging of 99mTc-MIBI-SPECT/ CT-negative patients with primary hyperparathyroidism and previous neck surgery.** T Traub-Weidinger, ME Mayerhoefer, O Koperek, M Mitterhauser, H Duan, G Karanikas, B Niederle, M Hoffmann. *Journal of Clinical Endocrinology and Metabolism*. 2014;99(11):4199-205.
 100. **The norepinephrine transporter in attention-deficit/hyperactivity disorder investigated with positron emission tomography.** T Vanicek, M Spies, C Rami-Mark, M Savli, A Höflich, GS Kranz, A Hahn, A Kutzelnigg, T Traub-Weidinger, M Mitterhauser, W Wadsak, M Hacker, ND Volkow, S Kasper, R Lanzenberger. *JAMA Psychiatry*. 2014;71(12):1340-9.
 101. **Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier.** M Bauer, R Karch, M Zeitlinger, J Stanek, C Philippe, W Wadsak, M Mitterhauser, W Jäger, H Haslacher, M Müller, O Langer. *Journal of Nuclear Medicine*. 2013;54(8):1181-7.
 102. **Application of image-derived and venous input functions in major depression using [carbonyl-11C]WAY-100635.** A Hahn, L Nics, P Baldinger, W Wadsak, M Savli, C Kraus, W Birkfellner, J Ungersboeck, D Haeusler, M Mitterhauser, G Karanikas, S Kasper, R Frey, R Lanzenberger. *Nuclear Medicine and Biology*. 2013;40(3):371-7.
 103. **Erratum: Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET (Molecular Psychiatry (2013) 18 (93-100) DOI: 10.1038/mp.2012.93).** R Lanzenberger, P Baldinger, A Hahn, J Ungersboeck, M Mitterhauser, D Winkler, Z Micskei, P Stein, G Karanikas, W Wadsak, S Kasper, R Frey. *Molecular Psychiatry*. 2013;18(10):1146.

104. **Impact of electroconvulsive therapy on 5-HT_{1A} receptor binding in major depression.** R Lanzenberger, P Baldinger, A Hahn, J Ungersboeck, M Mitterhauser, D Winkler, Z Micskei, P Stein, G Karanikas, W Wadsak, S Kasper, R Frey. *Molecular Psychiatry*. 2013;18(1).
105. **Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET.** R Lanzenberger, P Baldinger, A Hahn, J Ungersboeck, M Mitterhauser, D Winkler, Z Micskei, P Stein, G Karanikas, W Wadsak, S Kasper, R Frey. *Molecular Psychiatry*. 2013;18(1):93-100.
106. **Development and automation of a novel NET-PET tracer: [11C]Me@APPI.** C Mark, B Bornatowicz, M Mitterhauser, M Hendl, L Nics, D Haeusler, R Lanzenberger, ML Berger, H Spreitzer, W Wadsak. *Nuclear Medicine and Biology*. 2013;40(2):295-303.
107. **Gadoxetate-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET/MRI in patients with neuroendocrine tumours of the upper abdomen.** ME Mayerhoefer, A Ba-Ssalamah, M Weber, M Mitterhauser, H Eidherr, W Wadsak, M Raderer, S Trattnig, A Herneth, G Karanikas. *European Radiology*. 2013;23(7):1978-85.
108. **Synthesis, radiosynthesis and first in vitro evaluation of novel PET-tracers for the dopamine transporter: [11C]IPCIT and [18F]FE@IPCIT.** C Rami-Mark, B Bornatowicz, C Fink, P Otter, J Ungersboeck, C Vraka, D Haeusler, L Nics, H Spreitzer, M Hacker, M Mitterhauser, W Wadsak. *Bioorganic and Medicinal Chemistry*. 2013;21(24):7562-9.
109. **Reliable set-up for in-loop 11C-carboxylations using Grignard reactions for the preparation of [carbonyl-11C]WAY-100635 and [11C]-(+)-PHNO.** C Rami-Mark, J Ungersboeck, D Haeusler, L Nics, C Philippe, M Mitterhauser, M Willeit, R Lanzenberger, G Karanikas, W Wadsak. *Applied Radiation and Isotopes*. 2013;82:75-80.
110. **[18F]FMeNER-D2: Reliable fully-automated synthesis for visualization of the norepinephrine transporter.** C Rami-Mark, MR Zhang, M Mitterhauser, R Lanzenberger, M Hacker, W Wadsak. *Nuclear Medicine and Biology*. 2013;40(8):1049-54.
111. **Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling.** T Reiberger, BA Payer, P Schwabl, H Hayden, T Horvatits, B Jäger, T Hummel, M Mitterhauser, M Trauner, V Fuhrmann, B Angermayr, M Peck-Radosavljevic, L Vienna Hepatic Hemodynamic. *Liver International*. 2013;33(4):561-8.
112. **Syntheses of precursors and reference compounds of the melanin-concentrating hormone receptor 1 (MCHR1) Tracers [11C]SNAP-7941 and [18F]FE@SNAP for positron emission tomography.** E Schirmer, K Shanab, B Datterl, C Neudorfer, M Mitterhauser, W Wadsak, C Philippe, H Spreitzer. *Molecules*. 2013;18(10):12119-43.
113. **Influence of the HTR_{1A} polymorphism rs878567 on the serotonin 1a binding potential in vivo.** P Baldinger, A Hahn, M Friedl, GS Kranz, J Ungersböck, A Höflich, M Mitterhauser, D Rujescu, W Wadsak, R Lanzenberger, S Kasper. *Journal für Neurologie, Neurochirurgie und Psychiatrie*. 2012;13(1):36-8.
114. **Pgp-mediated interaction between (R)- 11CVerapamil and tariquidar at the human blood-brain barrier: A comparison with rat data.** M Bauer, M Zeitlinger, R Karch, P Matzneller, J Stanek, W Jäger, M Böhmendorfer, W Wadsak, M Mitterhauser, JP Bankstahl, W Löscher, M Koepp, C Kuntner, M Müller, O Langer. *Clinical Pharmacology and Therapeutics*. 2012;91(2):227-33.
115. **Synthesis of 2-(4-N-[11C]Methylaminophenyl)-6-Hydroxybenzothiazole ([11C]6-OH-BTA-1; [11C]PIB).** C Philippe, M Mitterhauser, W Wadsak. *Radiochemical Syntheses: Radiopharmaceuticals for Positron Emission Tomography*. 2012. p. 177-89.
116. **Synthesis of 3-Amino-4-[2-(N-Methyl-N-[11C]Methyl-Amino-Methyl)Phenylsulfanyl]-Benzonitrile ([11C]DASB).** D Haeusler, M Mitterhauser, W Wadsak. *Radiochemical Syntheses: Radiopharmaceuticals for Positron Emission Tomography*. 2012. p. 285-96.

117. **Synthesis of [⁶⁸Ga]Gallium Dota-(Tyr³)-Octreotide Acetate ([⁶⁸Ga]-Dotatoc).** H Eidherr, F Girschele, M Mitterhauser, W Wadsak. *Radiochemical Syntheses: Radiopharmaceuticals for Positron Emission Tomography*. 2012. p. 321-34.
118. **Combining image-derived and venous input functions enables quantification of serotonin-1A receptors with [carbonyl- ¹¹C]WAY-100635 independent of arterial sampling.** A Hahn, L Nics, P Baldinger, J Ungersböck, P Dolliner, R Frey, W Birkfellner, M Mitterhauser, W Wadsak, G Karanikas, S Kasper, R Lanzenberger. *NeuroImage*. 2012;62(1):199-206.
119. **Differential modulation of the default mode network via serotonin-1A receptors.** A Hahn, W Wadsak, C Windischberger, P Baldinger, AS Hoflich, J Losak, L Nics, C Philippe, GS Kranz, C Kraus, M Mitterhauser, G Karanikas, S Kasper, R Lanzenberger. *Proceedings of the National Academy of Sciences of the United States of America*. 2012;109(7):2619-24.
120. **Serotonin-1A receptor binding is positively associated with gray matter volume - A multimodal neuroimaging study combining PET and structural MRI.** C Kraus, A Hahn, M Savli, GS Kranz, P Baldinger, A Höflich, C Spindelegger, J Ungersboeck, D Haeusler, M Mitterhauser, C Windischberger, W Wadsak, S Kasper, R Lanzenberger. *NeuroImage*. 2012;63(3):1091-8.
121. **Prediction of SSRI treatment response in major depression based on serotonin transporter interplay between median raphe nucleus and projection areas.** R Lanzenberger, GS Kranz, D Haeusler, E Akimova, M Savli, A Hahn, M Mitterhauser, C Spindelegger, C Philippe, M Fink, W Wadsak, G Karanikas, S Kasper. *NeuroImage*. 2012;63(2):874-81.
122. **Radiosynthesis of [¹¹C]SNAP-7941-the first PET-tracer for the melanin concentrating hormone receptor 1 (MCHR1).** C Philippe, E Schirmer, M Mitterhauser, K Shanab, R Lanzenberger, G Karanikas, H Spreitzer, H Viernstein, W Wadsak. *Applied Radiation and Isotopes*. 2012;70(10):2287-94.
123. **FE@SNAP - A new PET tracer for the melanin concentrating hormone receptor 1 (MCHR1): Microfluidic and vessel-based approaches.** C Philippe, J Ungersboeck, E Schirmer, M Zdravkovic, L Nics, M Zeilinger, K Shanab, R Lanzenberger, G Karanikas, H Spreitzer, H Viernstein, M Mitterhauser, W Wadsak. *Bioorganic and Medicinal Chemistry*. 2012;20(19):5936-40.
124. **Normative database of the serotonergic system in healthy subjects using multi-tracer PET.** M Savli, A Bauer, M Mitterhauser, YS Ding, A Hahn, T Kroll, A Neumeister, D Haeusler, J Ungersboeck, S Henry, SA Isfahani, F Rattay, W Wadsak, S Kasper, R Lanzenberger. *NeuroImage*. 2012;63(1):447-59.
125. **Light-dependent alteration of serotonin-1A receptor binding in cortical and subcortical limbic regions in the human brain.** C Spindelegger, P Stein, W Wadsak, M Fink, M Mitterhauser, U Moser, M Savli, LK Mien, E Akimova, A Hahn, M Willeit, K Kletter, S Kasper, R Lanzenberger. *World Journal of Biological Psychiatry*. 2012;13(6):413-22.
126. **Optimization of [¹¹C]DASB-synthesis: Vessel-based and flow-through microreactor methods.** J Ungersboeck, C Philippe, D Haeusler, M Mitterhauser, R Lanzenberger, R Dudczak, W Wadsak. *Applied Radiation and Isotopes*. 2012;70(11):2615-20.
127. **Radiolabeling of [¹⁸F]altanserin - a microfluidic approach.** J Ungersboeck, S Richter, L Collier, M Mitterhauser, G Karanikas, R Lanzenberger, R Dudczak, W Wadsak. *Nuclear Medicine and Biology*. 2012;39(7):1087-92.
128. **Progesterone level predicts serotonin-1A receptor binding in the male human brain.** R Lanzenberger, M Mitterhauser, GS Kranz, C Spindelegger, W Wadsak, P Stein, U Moser, M Savli, K Kletter, S Kasper. *Neuroendocrinology*. 2011;94(1):84-8.
129. **Optimization of the radiosynthesis of the Alzheimer tracer 2-(4-N-[¹¹C]methylaminophenyl)-6-hydroxybenzothiazole ([¹¹C]PIB).** C Philippe, D Haeusler, M Mitterhauser, J Ungersboeck, H Viernstein, R Dudczak, W Wadsak. *Applied Radiation and Isotopes*. 2011;69(9):1212-7.
130. **Microfluidic preparation of [¹⁸F]FE@SUPPY and [¹⁸F]FE@SUPPY:2 - comparison with conventional radiosyntheses.** J Ungersboeck, C Philippe, LK Mien,

- D Haeusler, K Shanab, R Lanzenberger, H Spreitzer, BK Keppler, R Dudczak, K Kletter, M Mitterhauser, W Wadsak. *Nuclear Medicine and Biology*. 2011;38(3):427-34.
131. **Central serotonin 1A receptor binding in temporal lobe epilepsy: A [carbonyl-11C]WAY-100635 PET study.** E Assem-Hilger, R Lanzenberger, M Savli, W Wadsak, M Mitterhauser, LK Mien, E Stögmann, C Baumgartner, K Kletter, S Asenbaum. *Epilepsy and Behavior*. 2010;19(3):467-73.
132. **Escitalopram enhances the association of serotonin-1A autoreceptors to heteroreceptors in anxiety disorders.** A Hahn, R Lanzenberger, W Wadsak, C Spindelegger, U Moser, LK Mien, M Mitterhauser, S Kasper. *Journal of Neuroscience*. 2010;30(43):14482-9.
133. **Cortisol plasma levels in social anxiety disorder patients correlate with serotonin-1A receptor binding in limbic brain regions.** R Lanzenberger, W Wadsak, C Spindelegger, M Mitterhauser, E Akimova, LK Mien, M Fink, U Moser, M Savli, GS Kranz, A Hahn, K Kletter, S Kasper. *International Journal of Neuropsychopharmacology*. 2010;13(9):1129-43.
134. **Hypothalamic serotonin-1A receptor binding measured by PET predicts the plasma level of dehydroepiandrosterone sulfate in healthy women.** U Moser, W Wadsak, C Spindelegger, M Mitterhauser, LK Mien, C Bieglmayer, K Kletter, S Kasper, R Lanzenberger. *Neuroscience Letters*. 2010;476(3):161-5.
135. **Aggression is related to frontal serotonin-1A receptor distribution as revealed by PET in healthy subjects (Human Brain Mapping (2008) DOI: 10.1002/hbm.20687).** AV Witte, A Flöel, P Stein, M Savli, LK Mien, W Wadsak, C Spindelegger, U Moser, M Fink, A Hahn, M Mitterhauser, K Kletter, S Kasper, R Lanzenberger. *Human Brain Mapping*. 2010;31(2):339.
136. **Lateralization of the serotonin-1A receptor distribution in language areas revealed by PET.** M Fink, W Wadsak, M Savli, P Stein, U Moser, A Hahn, LK Mien, K Kletter, M Mitterhauser, S Kasper, R Lanzenberger. *NeuroImage*. 2009;45(2):598-605.
137. **Radiosynthesis of a novel potential adenosine A3 receptor ligand, 5-ethyl 2,4-diethyl-3-((2-[18F]fluoroethyl)sulfanylcarbonyl) 6-phenylpyridine-5-carboxylate ([18F]FE @ SUPPY:2).** D Haeusler, M Mitterhauser, LK Mien, K Shanab, RR Lanzenberger, E Schirmer, J Ungersboeck, L Nics, H Spreitzer, H Viernstein, R Dudczak, K Kletter, W Wadsak. *Radiochimica Acta*. 2009;97(12):753-8.
138. **Simple and rapid preparation of [11C]DASB with high quality and reliability for routine applications.** D Haeusler, LK Mien, L Nics, J Ungersboeck, C Philippe, RR Lanzenberger, K Kletter, R Dudczak, M Mitterhauser, W Wadsak. *Applied Radiation and Isotopes*. 2009;67(9):1654-60.
139. **Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats.** T Reiberger, B Angermayr, P Schwabl, N Rohr-Udilova, M Mitterhauser, A Gangl, M Peck-Radosavljevic. *Journal of Hepatology*. 2009;51(5):865-73.
140. **Influence of escitalopram treatment on 5-HT 1A receptor binding in limbic regions in patients with anxiety disorders.** C Spindelegger, R Lanzenberger, W Wadsak, LK Mien, P Stein, M Mitterhauser, U Moser, A Holik, L Pezawas, K Kletter, S Kasper. *Molecular Psychiatry*. 2009;14(11):1040-50.
141. **Aggression is related to frontal serotonin-1A receptor distribution as revealed by PET in healthy subjects.** AV Witte, A Flöel, P Stein, M Savli, LK Mien, W Wadsak, C Spindelegger, U Moser, M Fink, A Hahn, M Mitterhauser, K Kletter, S Kasper, R Lanzenberger. *Human Brain Mapping*. 2009;30(8):2558-70.
142. **Multimodal imaging of human early visual cortex by combining functional and molecular measurements with fMRI and PET.** F Gerstl, C Windischberger, M Mitterhauser, W Wadsak, A Holik, K Kletter, E Moser, S Kasper, R Lanzenberger. *NeuroImage*. 2008;41(2):204-11.
143. **Synthesis of in vivo metabolites of the new adenosine A3 receptor PET-radiotracer[18F]Fe@SUPPY.** K Shanab, W Wadsak, LK Mien, M Mitterhauser, W Holzer, V Polster, H Viernstein, H Spreitzer. *Heterocycles*. 2008;75(2):339-56.
144. **The serotonin-1A receptor distribution in healthy men and women measured by PET and [carbonyl-11C]WAY-100635.** P Stein, M Savli, W Wadsak, M

- Mitterhauser, M Fink, C Spindelegger, LK Mien, U Moser, R Dudczak, K Kletter, S Kasper, R Lanzenberger. *European Journal of Nuclear Medicine and Molecular Imaging*. 2008;35(12):2159-68.
145. **Reduced Serotonin-1A Receptor Binding in Social Anxiety Disorder.** RR Lanzenberger, M Mitterhauser, C Spindelegger, W Wadsak, N Klein, LK Mien, A Holik, T Attarbaschi, N Mossaheb, J Sacher, T Geiss-Granadia, K Kletter, S Kasper, J Tauscher. *Biological Psychiatry*. 2007;61(9):1081-9.
 146. **In vivo disposition of irinotecan (CPT-11) and its metabolites in combination with the monoclonal antibody cetuximab.** DE Ettlinger, M Mitterhauser, W Wadsak, E Ostermann, A Farkouh, J Schueller, M Czejka. *Anticancer Research*. 2006;26(2 B):1337-41.
 147. **11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer.** S Wachter, S Tomek, A Kurtaran, N Wachter-Gerstner, B Djavan, A Becherer, M Mitterhauser, G Dobrozemsky, S Li, R Pötter, R Dudczak, K Kletter. *Journal of Clinical Oncology*. 2006;24(16):2513-9.
 148. **[18F]FETO for adrenocortical PET imaging: A pilot study in healthy volunteers.** W Wadsak, M Mitterhauser, G Rendl, M Schuetz, LK Mien, DE Ettlinger, R Dudczak, K Kletter, G Karanikas. *European Journal of Nuclear Medicine and Molecular Imaging*. 2006;33(6):669-72.
 149. **NCA nucleophilic radiofluorination on substituted benzaldehydes for the preparation of [18F]fluorinated aromatic amino acids.** W Wadsak, B Wirl-Sagadin, M Mitterhauser, LK Mien, DE Ettlinger, BK Keppler, R Dudczak, K Kletter. *Applied Radiation and Isotopes*. 2006;64(3):355-9.
 150. **In vitro and in vivo evaluation of [18F]ciprofloxacin for the imaging of bacterial infections with PET.** O Langer, M Brunner, M Zeitlinger, S Ziegler, U Müller, G Dobrozemsky, E Lackner, C Joukhadar, M Mitterhauser, W Wadsak, E Minar, R Dudczak, K Kletter, M Müller. *European Journal of Nuclear Medicine and Molecular Imaging*. 2005;32(2):143-50.
 151. **[18F]ciprofloxacin, a new positron emission tomography tracer for noninvasive assessment of the tissue distribution and pharmacokinetics of ciprofloxacin in humans.** M Brunner, O Langer, G Dobrozemsky, U Müller, M Zeitlinger, M Mitterhauser, W Wadsak, R Dudczak, K Kletter, M Müller. *Antimicrobial Agents and Chemotherapy*. 2004;48(10):3850-7.
 152. **Bone lesion detection with carrier-added 99mTc-edtmp in comparison with 99mTc-dpd.** BJ Fueger, M Mitterhauser, W Wadsak, S Ofluoglu, T Traub, G Karanikas, R Dudczak, C Pirich. *Nuclear Medicine Communications*. 2004;25(4):361-5.
 153. **Positron emission tomography imaging of adrenal masses: 18F-fluorodeoxyglucose and the 11 β -hydroxylase tracer 11C-metomidate.** G Zettinig, M Mitterhauser, W Wadsak, A Becherer, C Pirich, H Vierhapper, B Niederle, R Dudczak, K Kletter. *European Journal of Nuclear Medicine and Molecular Imaging*. 2004;31(9):1224-30.
 154. **A general method for the fluorine-18 labelling of fluoroquinolone antibiotics.** O Langer, M Mitterhauser, W Wadsak, M Brunner, U Müller, K Kletter, M Müller. *Journal of Labelled Compounds and Radiopharmaceuticals*. 2003;46(8):715-27.
 155. **Synthesis of fluorine-18-labeled ciprofloxacin for PET studies in humans.** O Langer, M Mitterhauser, M Brunner, M Zeitlinger, W Wadsak, BX Mayer, K Kletter, M Müller. *Nuclear Medicine and Biology*. 2003;30(3):285-91.
 156. **Radiosynthesis of 3-(2'-[18F]fluoro)-flumazenil ([18F]FFMZ).** W Wadsak, M Mitterhauser, LK Mien, S Tögel, B Keppler, R Dudczak, K Kletter. *Journal of Labelled Compounds and Radiopharmaceuticals*. 2003;46(13):1229-40.
 157. **Pharmacokinetics of 2-methoxyphenylmetyrapone and 2-bromophenylmetyrapone in rats.** IP Nnane, MC Tsai, G Lin, LA Damani, M Mitterhauser, I Zolle. *European Journal of Drug Metabolism and Pharmacokinetics*. 1999;24(1):23-9.
 158. **Simultaneous analysis of 2-methoxyphenylmetyrapone and its seven potential members of high-performance liquid chromatography.** LA Damani, MC

- Tsai, G Lin, M Mitterhauser, I Zolle. *Journal of Chromatography B: Biomedical Applications*. 1997;704(1-2):315-23.
159. **Spectral and chromatographic properties of 2-methoxyphenylmetyrapone and its potential metabolites.** YP Ho, G Lin, LA Damani, M Mitterhauser, I Zolle. *Journal of Pharmaceutical and Biomedical Analysis*. 1997;15(4):479-86.
160. **Urinary metabolic profile in rat of 1-(2-methoxyphenyl)-2-methyl-2-(3-pyridyl)-1-propanone: A potential radioligand for functional diagnosis of adrenal pathology.** LA Damani, M Mitterhauser, G Lin, YP Ho, I Zolle. *Xenobiotica*. 1996;26(2):211-9.
161. **Metabolic and pharmacokinetic considerations in the design of 2-phenyl substituted metyrapone derivatives: 2-methoxyphenylmetyrapone as a radioligand for functional diagnosis of adrenal pathology.** LA Damani, M Mitterhauser, I Zolle, G Lin, E Oehler, YP Ho. *Nuclear Medicine and Biology*. 1995;22(8):1067-74.
162. **Some new methods for the synthesis of cardiac neurotransmission PET radiotracers.** K Någren, C Halldin, CG Swahn, KO Schoeps, O Langer, M Mitterhauser, I Zolle. *Nuclear Medicine and Biology*. 1995;22(8):1037-43.